U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease
Publishing timestamp: 2023-12-08 12:41:10
Summary
The U.S. FDA has approved Casgevy, the first gene-editing treatment using CRISPR technology, for patients with sickle cell disease. The treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, aims to edit a person's genes to treat the blood disorder. While it represents a significant scientific advancement, the high cost and complexity of the treatment may limit its accessibility. Another gene therapy by Bluebird Bio, called Lyfgenia, was also approved for the same condition.
Sentiment: MIXED
Keywords: health care industry, biotech and pharmaceuticals, united states, science, crispr therapeutics ag, breaking news: business, vertex pharmaceuticals inc, business news, business,
Source: https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html